Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
3. Diabetes: Medtronic retires Sof-sensor glucose sensor
Medtronic told patients that it plans to sunset its Sof-sensor glucose sensor as of Dec. 1 and move patients to its newer Enlite device.
In a Sept. 30 notice, Fridley, Minn.-based Medtronic said it’s discontinuing the Sof-sensor, its oldest continuous glucose monitoring sensor, isn’t related to the sensor’s safety or performance. Read more
2. TransMedics wins FDA panel date for organ preservation device
The FDA plans to convene an advisory panel to review the pre-market approval bid for the organ preservation device made by TransMedics.
The FDA’s Gastroenterology & Urology Devices panel is slated to meet Nov. 18 to discuss Andover, Mass.-based TransMedics’ PMA bid for its Organ Care System, which is designed to perfuse a donor heart with warm, oxygenated blood and monitor its status until transplantation. Read more
1. Boston Scientific slips $200m patent spat with stent pioneer Jang
Boston Scientific escaped a long-running royalties dispute with coronary stent pioneer Dr. David Jang that could have cost it $200 million.
Judge Virginia Phillips of the U.S. District Court for Central California found Sept. 29 that Jang’s claims covered previous patents, triggering the ensnarement defense barring a patentee from asserting a scope of equivalency that would encompass, or ensnare, the prior art. Read more